
EpiEndo Pharmaceuticals pushes COPD candidate
The Icelandic inflammation specialist received regulatory approval for its Phase IIa trial of Barriolide™ (EP395) in patients with Chronic...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

CatalYm GmbH raises €50m to push visugromab development
Following a €60m Series B financing in 2020, Martinsried-based CatalYm GmbH announced the closing of a Series C financing round of €50m. The...

BioNTech and Ryvu Therapeutics enter into global collaboration
BioNTech SE and Ryvu Therapeutics S.A. announced that the companies have entered into a multi-target research collaboration targeting immune...

Novadip Biosciences SA raises €40m
Belgian regenerative medicine specialist Novadip Biosciences has raised €40m to push clinical development of its two investigational adipose stem...

€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...